The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study.
Rosa SciutoSandra ReaSara UnganiaAntonella TestaValentina DiniMaria Antonella TabocchiniClarice PatronoAntonella SorianiValentina PalmaRaffaella MarconiLidia StrigariPublished in: Journal of experimental & clinical cancer research : CR (2021)
The pilot study has been approved from the Ethics Committee of Regina Elena National Cancer Institute (N:RS1083/18-2111).